Cargando...
Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy
INTRODUCTION: Deciding on an optimal medication choice for type 2 diabetes is often challenging, due to the increasing number of treatment options. Canagliflozin is a novel glucose-lowering agent belonging to sodium–glucose co-transporter 2 (SGLT2) inhibitors. AIM: The aim of this study was to exami...
Gardado en:
| Publicado en: | Core Evid |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5358960/ https://ncbi.nlm.nih.gov/pubmed/28352212 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S109654 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|